Hepatitis A Virus: Diagnosis, Management, and Prevention
Diagnosis
Hepatitis A is diagnosed by detecting IgM anti-HAV antibodies in serum, which indicate acute infection, while IgG anti-HAV antibodies indicate past infection or immunity. 1 The infection presents as acute hepatitis with self-limited disease that does not progress to chronic infection. Up to 20% of patients may experience prolonged or relapsing courses, and less than 1% develop acute liver failure 1.
Post-Exposure Prophylaxis (PEP)
For post-exposure prophylaxis, hepatitis A vaccine is now the preferred agent for persons aged ≥12 months, administered within 2 weeks of exposure 2, 3. This represents a significant shift from previous reliance on immune globulin (IG).
Age-Specific PEP Recommendations:
- <12 months: IG only at 0.1 mL/kg 2
- 12 months–40 years (healthy): 1 dose of HepA vaccine 2
- >40 years (healthy): 1 dose of HepA vaccine; providers may also administer IG (0.1 mL/kg) based on risk assessment 2
- ≥12 months (immunocompromised or chronic liver disease): Both vaccine and IG (0.1 mL/kg) administered simultaneously at different anatomic sites 2
The effectiveness of HepA vaccine for PEP is 97.6%, which is statistically equivalent to IG's 98.3% effectiveness 4. Vaccine offers the advantages of inducing active immunity, providing long-term protection, easier administration, and greater availability compared to IG 2.
Important Caveat for Older Adults:
While vaccine is recommended for adults >40 years, immunogenicity may be slightly diminished in this age group, particularly in the very oldest adults 5. However, seroprotection rates equalize by 30 days post-vaccination 5. The vaccine should be administered as soon as possible within the 14-day window for optimal immune response.
Pre-Exposure Vaccination
ACIP recommends routine vaccination of all children aged 12-23 months, with catch-up vaccination for children and adolescents aged 2-18 years who have not previously received HepA vaccine 3.
Adult Vaccination Indications:
- Adults at risk for HAV infection or severe disease
- Adults requesting protection without specific risk factors
- International travelers 3
Travel-Related Vaccination:
- Infants 6-11 months traveling internationally: Administer 1 dose of HepA vaccine (this dose does not count toward the routine 2-dose series, which should begin at 12 months) 2
- Infants <6 months: IG at 0.1-0.2 mL/kg depending on travel duration 2
- ≥12 months: Administer HepA vaccine as soon as travel is considered 2
Important note: Measles, mumps, and rubella (MMR) vaccine should not be administered for at least 3 months after IG receipt, but can be given simultaneously with HepA vaccine 2. This makes HepA vaccine the preferred option for infants 6-11 months traveling internationally who also need MMR.
Vaccination Schedule and Duration of Protection
The standard series consists of 2 doses, with the second dose administered at least 6 months after the first 2. Vaccine-induced antibodies confer long-term protection for at least 25 years, though data beyond this period is limited 6. IgG anti-HAV antibodies produced after infection persist for life and protect against reinfection 1, 3.
Management
Hepatitis A is a self-limited disease requiring supportive care. Attention should be given to host factors that affect disease severity: immunological status, age, pregnancy, and underlying hepatic diseases 1. No specific antiviral therapy exists for acute hepatitis A.
Prevention Beyond Vaccination
- Improving hygiene and sanitation
- Rapid identification of outbreaks
- Fast and accurate intervention in outbreak control 1
Universal childhood vaccination programs have proven highly effective: evidence from Alaska demonstrates that routine early childhood HepA vaccination can eliminate transmission in areas that previously experienced repeat outbreaks 6. Over 25 countries worldwide have implemented such programs, resulting in substantial reductions in HAV incidence 1.